glp-1 agonist weight loss mechanism Frontiers The GLP-1 Agonists and Obesity:
Description
holds the Pasman chair
Most people tolerate both medication types well after initial adjustment
Hong B, Lee H, Choi A, Kim WJ, Cho YM, Yon DK, et al
G., Mace, K
Demonstrating efficacy in obesity-related comorbidities will be paramount in order to achieve reimbursement in Europe, yet it will take time for trials focused on these co-morbidities to translate into label expansion and revenues
